87 related articles for article (PubMed ID: 7350713)
1. Immunologic aspects of unknown primary melanoma.
Giuliano AE; Moseley HS; Irie RF; Golub SH; Morton DL
Surgery; 1980 Jan; 87(1):101-5. PubMed ID: 7350713
[TBL] [Abstract][Full Text] [Related]
2. Some aspects of cell-mediated hypersensitivity in patients with melanoma.
Moszkowska G; Jassem J; Kondrat W; Kopacz A; Goszczyńska E
Arch Immunol Ther Exp (Warsz); 1980; 28(4):655-60. PubMed ID: 6970028
[TBL] [Abstract][Full Text] [Related]
3. Demonstration of lymphocyte blastogenesis--inhibiting factors in sera of melanoma patients.
Rangel DM; Golub SH; Morton DL
Surgery; 1977 Aug; 82(2):224-32. PubMed ID: 877866
[TBL] [Abstract][Full Text] [Related]
4. Correlations among cutaneous reactivity to DNCB, PHA-induced lymphocyte blastogenesis and peripheral blood E rosettes.
Catalona WJ; Tarpley JL; Potvin C; Chretien PB
Clin Exp Immunol; 1975 Feb; 19(2):327-33. PubMed ID: 1082390
[TBL] [Abstract][Full Text] [Related]
5. DNCB reactivity and prognosis in 419 patients with malignant melanoma.
Camacho ES; Pinsky CM; Braun DW; Golbey RB; Fortner JG; Wanebo HJ; Oettgen HF
Cancer; 1981 May; 47(10):2446-50. PubMed ID: 7272900
[TBL] [Abstract][Full Text] [Related]
6. A prospective study of immune responsiveness in human melanoma. I. Assessment of initial pretreatment status with stage of disease.
Pritchard DJ; Ritts RE; Taylor WF; Miller GC
Cancer; 1978 Jun; 41(6):2165-73. PubMed ID: 306870
[TBL] [Abstract][Full Text] [Related]
7. [Correlation of the level of humoral cytotoxins and delayed hypersensitivity skin reactions with survival of patients with melanoma of the skin].
Korosteleva TA; Vagner RI; Veresova OV; Potapenkova LS
Vopr Onkol; 1983; 29(4):38-40. PubMed ID: 6858049
[TBL] [Abstract][Full Text] [Related]
8. [Skin reactions of delayed hypersensitivity in melanoblastoma].
Ryzhkov VI; Potapenkova LS; Korosteleva TA; Khachaturian LM
Vopr Onkol; 1979; 25(4):3-6. PubMed ID: 433214
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1976 Nov; 88(21):690-6. PubMed ID: 1007279
[TBL] [Abstract][Full Text] [Related]
10. Malignant melanoma. Delayed hypersensitivity skin testing.
Roses DF; Campion JF; Harris MN; Gumport SL
Arch Surg; 1979 Jan; 114(1):35-8. PubMed ID: 758875
[TBL] [Abstract][Full Text] [Related]
11. [Decrease in immunoreactivity in melanoma. Analysis of DNCB tests in the literature].
Remy W; Dorn R; Ulm K; Mayerhausen W
Z Hautkr; 1986 Dec; 61(24):1767-77. PubMed ID: 3825218
[TBL] [Abstract][Full Text] [Related]
12. Effect of BCG (Tice strain) on primary sensitization to 2,4-dinitrochlorobenzene and on established delayed hypersensitivity in human malignant melanoma.
Mavligit GM; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1976 Oct; 57(4):749-51. PubMed ID: 1003526
[TBL] [Abstract][Full Text] [Related]
13. Long-term spontaneous regression of malignant melanoma with visceral metastases. Report of a case with immunologic profile.
Bulkley GB; Cohen MH; Banks PM; Char DH; Ketcham AS
Cancer; 1975 Aug; 36(2):485-94. PubMed ID: 1157014
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy].
Lejeune FJ; Bernheim JL; Vanwijck R
Acta Chir Belg; 1974 Mar; 73(2):265-93. PubMed ID: 4450923
[No Abstract] [Full Text] [Related]
15. [Testing of cellular immune reactivity in melanoma patients with diphenylcyclopropenone in comparison to dinitrochlorobenzol].
Mayerhausen W; Remy W
Hautarzt; 1987 Aug; 38(8):449-52. PubMed ID: 3654215
[TBL] [Abstract][Full Text] [Related]
16. [A correlation between the histological parameters such as stromal reaction and cell-mediated immune-structure of the regional lymph nodes, and the delayed cutaneous hypersensitive reaction toward DNCB in cervical cancer (author's transl)].
Obata N; Kodama S; Hando T; Hirogami T; Takeuchi S
Nihon Sanka Fujinka Gakkai Zasshi; 1980 May; 32(5):550-8. PubMed ID: 7240843
[TBL] [Abstract][Full Text] [Related]
17. Cell-mediated immunity in patients with carcinoma: correlation between clinical stage and immunocompetence.
Kopersztych S; Rezkallah MT; Miki SS; Naspitz CK; Mendes NF
Cancer; 1976 Sep; 38(3):1149-54. PubMed ID: 1085193
[TBL] [Abstract][Full Text] [Related]
18. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
[TBL] [Abstract][Full Text] [Related]
19. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
Knopf B; Wätzig V; Knöll B
Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
[TBL] [Abstract][Full Text] [Related]
20. Skin tests with autologous cholesteryl hemisuccinate-treated tumor cells, DNCB and PPD and their relationship to prognosis in malignant melanoma patients.
Munzarová M; Mechl Z; Kovarík J; Kolcová V
Neoplasma; 1988; 35(2):229-34. PubMed ID: 3374711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
